|214.91||+1.27||+0.59%||Vol 1.04M||1Y Perf -11.60%|
|Sep 23rd, 2021 13:39 DELAYED|
|0.06 0.03%||- -|
|Target Price||252.39||Analyst Rating||Moderate Buy 2.11|
|Potential %||17.42||Finscreener Ranking||★ 42.62|
|Insiders Trans % 3/6/12 mo.||-/-100/-100||Value Ranking||★★ 46.51|
|Insiders Value % 3/6/12 mo.||-/-100/-100||Growth Ranking||★★★ 53.17|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-100||Income Ranking||★★+ 41.04|
|Price Range Ratio 52W %||6.97||Earnings Rating||Neutral|
|Market Cap||122.04B||Earnings Date||27th Oct 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||27th Oct 2021|
|Estimated EPS Next Report||4.21|
|EPS Growth Next 5 Years %||8.40|
|Avg. Weekly Volume||2.91M|
|Avg. Monthly Volume||2.59M|
|Avg. Quarterly Volume||2.41M|
Amgen Inc. (NASDAQ: AMGN) stock closed at 213.64 per share at the end of the most recent trading day (a -0.8% change compared to the prior day closing price) with a volume of 2.54M shares and market capitalization of 122.04B. Is a component of S&P 500, NASDAQ 100, Dow Jones 30, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 24300 people. Amgen Inc. CEO is Robert A. Bradway.
The one-year performance of Amgen Inc. stock is -11.6%, while year-to-date (YTD) performance is -7.08%. AMGN stock has a five-year performance of 22.22%. Its 52-week range is between 210.28 and 276.69, which gives AMGN stock a 52-week price range ratio of 6.97%
Amgen Inc. currently has a PE ratio of 22.00, a price-to-book (PB) ratio of 14.88, a price-to-sale (PS) ratio of 4.79, a price to cashflow ratio of 13.20, a PEG ratio of 2.32, a ROA of 8.95%, a ROC of 15.82% and a ROE of 58.95%. The company’s profit margin is 22.34%, its EBITDA margin is 43.80%, and its revenue ttm is $25.48 Billion , which makes it $44.88 revenue per share.
Of the last four earnings reports from Amgen Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $4.21 for the next earnings report. Amgen Inc.’s next earnings report date is 27th Oct 2021.
The consensus rating of Wall Street analysts for Amgen Inc. is Moderate Buy (2.11), with a target price of $252.39, which is +17.42% compared to the current price. The earnings rating for Amgen Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Amgen Inc. has a dividend yield of 3.27% with a dividend per share of $7.04 and a payout ratio of 54.00%.
Amgen Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 7.03, ATR14 : 4.00, CCI20 : -105.30, Chaikin Money Flow : -0.07, MACD : -3.94, Money Flow Index : 37.96, ROC : -5.62, RSI : 34.55, STOCH (14,3) : 1.31, STOCH RSI : 0.06, UO : 42.22, Williams %R : -98.69), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Amgen Inc. in the last 12-months were: David M. Reese (Option Excercise at a value of $125 787), Jonathan P. Graham (Sold 11 110 shares of value $2 627 625 ), Nancy A. Grygiel (Option Excercise at a value of $406 500), Nancy A. Grygiel (Sold 2 500 shares of value $631 272 ), Robert A. Bradway (Option Excercise at a value of $4 019 715), Robert Sanders Williams (Sold 750 shares of value $183 043 ), Ronald D. Sugar (Option Excercise at a value of $358 200), Ronald D. Sugar (Sold 5 000 shares of value $1 206 490 )
Fri, 17 Sep 2021 16:50 GMT Amgen (AMGN) Receives a Hold from William Blair- TipRanks. All rights reserved.
Fri, 06 Aug 2021 09:35 GMT Heres What Amgens Newly Added Risk Factors Reveal- TipRanks. All rights reserved.
Wed, 04 Aug 2021 14:48 GMT Analysts Cautious of Amgen After Lukewarm Q2- TipRanks. All rights reserved.
Wed, 04 Aug 2021 12:25 GMT Analysts Offer Insights on Healthcare Companies: Addus Homecare (ADUS), Amgen (AMGN) and AstraZeneca (AZN)- TipRanks. All rights reserved.
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.